Journal
CANCER CELL
Volume 27, Issue 4, Pages 533-546Publisher
CELL PRESS
DOI: 10.1016/j.ccell.2015.03.010
Keywords
-
Categories
Funding
- Cycle for Survival
- Banco Bilbao Vizcaya Argentaria (BBVA) Foundation (Tumor Biomarker Research Program)
- Molecular Cytology Core Facility-Core grant [P30 CA0087748]
- NIH Training Grant [T32 CA-71345-15]
- NIH Director's Award [DP2 CA174497]
Ask authors/readers for more resources
Phosphoinositide-3-kinase (PI3K)-alpha inhibitors have shown clinical activity in squamous cell carcinomas (SCCs) of head and neck (H&N) bearing PIK3CA mutations or amplification. Studying models of therapeutic resistance, we have observed that SCC cells that become refractory to PI3K alpha inhibition maintain PI3K-independent activation of the mammalian target of rapamycin (mTOR). This persistent mTOR activation is mediated by the tyrosine kinase receptor AXL. AXL is overexpressed in resistant tumors from both laboratory models and patients treated with the PI3K alpha inhibitor BYL719. AXL dimerizes with and phosphorylates epidermal growth factor receptor (EGFR), resulting in activation of phospholipase C gamma (PLC gamma)-protein kinase C (PKC), which, in turn, activates mTOR. Combined treatment with PI3K alpha and either EGFR, AXL, or PKC inhibitors reverts this resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available